COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,732 Articles (22,502 medRxiv, 8,230 bioRxiv)

Most recent first Previous |  Page 874: Articles 8731-8740  | Next

A novel consensus-based computational pipeline for rapid screening of antibody therapeutics for efficacy against SARS-CoV-2 variants of concern including omicron variant
Kumar, N., Kaushik, R., Zhang, K. Y. J., Uversky, V. N., Srivastava, P., Sahu, U., Sood, R., Bhatia, S.
10.1101/2022.02.11.480177 — Posted: 2022-02-15
SARS-CoV-2-specific T cells associate with reduced lung function and inflammation in pulmonary post-acute sequalae of SARS-CoV-2
Littlefield, K., Watson, R., Schneider, J., Neff, C., Yamada, E., Zhang, M., Campbell, T., Falta, M., Jolley, S., Fontenot, A., Palmer, B.
10.1101/2022.02.14.480317 — Posted: 2022-02-15
Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose
Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Ben Tanfous, T., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., Raspe, R., Schaefer-Babajew, D., Shimeliovich, I., Daga, M., Yao, K.-H., Schmidt, F., Millard, K. G., Turroja, M., Jankovic, M., Oliveira, T. Y., Gazumyan, A., Caskey, M., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M.
10.1101/2022.02.14.480394 — Posted: 2022-02-15
Omicron-Based Vaccine Candidate Elicits Potent Neutralizing Antibodies in the Animal Model
Abdoli, A., Khanali, J., Azangou-Khyavy, M., Abbasi-Kangevari, M., Ghamari, S.-H., Malekpour, M.-R., Jamshidi, H., Lari Baghal, M., Taqavian, M., Jalili, H.
10.1101/2022.02.11.480131 — Posted: 2022-02-15
Surveillance of Myopericarditis following COVID-19 Booster Dose Vaccination in a Large Integrated Health System
Sharff, K. A., Dancoes, D. M., Longueil, J. L., Lewis, P. F., Johnson, E. S.
10.1101/2022.02.08.22270635 — Posted: 2022-02-15
Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic review and meta-analysis with meta regression analyzing influencing factors
Bruemmer, L. E., Katzenschlager, S., McGrath, S., Schmitz, S., Gaeddert, M., Erdmann, C., Bota, M., Grilli, M., Larmann, J., Weigand, M. A., Pollock, N. R., Mace, A., Erkosar, B., Carmona, S., Sacks, J. A., Ongarello, S., Denkinger, C. M.
10.1101/2022.02.11.22270831 — Posted: 2022-02-15
SARS-CoV-2 variants of concern Alpha and Delta show increased viral load in saliva
King, K. L., Wilson, S., Napolitano, J. M., Sell, K. J., Rennert, L., Parkinson, C. J., Dean, D.
10.1101/2022.02.10.22270797 — Posted: 2022-02-15
COVID-19 onset reduced the sex ratio at birth in South Africa
Masukume, G., Ryan, M., Masukume, R., Zammit, D., Grech, V., Mapanga, W.
10.1101/2022.02.07.22270630 — Posted: 2022-02-15
Co-infection with SARS-COV-2 Omicron and Delta Variants Revealed by Genomic Surveillance
Rockett, R. J., Draper, J., Gall, M., Sim, E. M., Arnott, A., Agius, J. E., Johnson-Mackinnon, J., Martinez, E., Drew, A. P., Lee, C., Ngo, C., Ramsperger, M., Ginn, A. N., Wang, Q., Fennell, M., Ko, D., Huston, L., Kairaitis, L., Holmes, E. C., O'Sullivan, M. N., Chen, S. C.-A., Kok, J., Dwyer, D. E., Sintchenko, V.
10.1101/2022.02.13.22270755 — Posted: 2022-02-15
Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
Lowe, D. M., Brown, L.-A. K., Chowdhury, K., Davey, S., Yee, P., Ikeji, F., Ndoutoumou, A., Shah, D., Lennon, A., Rai, A., Agyeman, A. A., Checkley, A., Longley, N., Dehbi, H.-M., Freemantle, N., Breuer, J., Standing, J. F., FLARE Investigators
10.1101/2022.02.11.22270775 — Posted: 2022-02-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).